How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
DNA Ginkgo Bioworks Holdings, Inc.
Dans un jugement du 10 décembre 2025, le tribunal administratif de Toulouse a annulé une délibération instaurant une autorisation spéciale d’absence (ASA) pour la réalisation de soins en rapport avec ...
Abstract: Complicated deformation problems are frequently encountered in medical image registration tasks. Although various advanced registration models have been proposed, accurate and efficient ...
RAPTOR introduces a novel approach to retrieval-augmented language models by constructing a recursive tree structure from documents. This allows for more efficient and context-aware information ...
This project is intended for enumerating PCI devices in the system without any interferences from OS. Hopefully the following commands can help you setup and build ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback